Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bill H Chang

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Blood Advances|January 25, 2022
Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemiaStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Leukemia|February 26, 2020
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemiaChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Science Translational Medicine|September 2, 2016
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemiaJessica T Leonard, Joelle S J Rowley, Christopher A Eide, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2009
RNAi screen for rapid therapeutic target identification in leukemia patientsJeffrey W Tyner, Michael W Deininger, Marc M Loriaux, et al.
Journal of Hematology & Oncology|April 22, 2015
YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathwayBill H Chang, Kara Johnson, Dorian LaTocha, et al.
Science Signaling|July 19, 2018
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemiaChelsea Jenkins, Samuel B Luty, Julia E Maxson, et al.
Cancer Research|June 3, 2015
Therapeutically Targetable ALK Mutations in LeukemiaJulia E Maxson, Monika A Davare, Samuel B Luty, et al.
Haematologica|July 8, 2021
Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemiaJessica Leonard, Joelle Sj Wolf, Michelle Degnin, et al.
Experimental Hematology|April 24, 2017
Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemiaTakayo Sasaki, Juan Carlos Rivera-Mulia, Daniel Vera, et al.
Oncotarget|October 6, 2016
Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemiaNameeta P Richard, Raffaella Pippa, Megan M Cleary, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Blood Advances|January 25, 2022
Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemiaStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Leukemia|February 26, 2020
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemiaChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Science Translational Medicine|September 2, 2016
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemiaJessica T Leonard, Joelle S J Rowley, Christopher A Eide, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2009
RNAi screen for rapid therapeutic target identification in leukemia patientsJeffrey W Tyner, Michael W Deininger, Marc M Loriaux, et al.
Journal of Hematology & Oncology|April 22, 2015
YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathwayBill H Chang, Kara Johnson, Dorian LaTocha, et al.
Science Signaling|July 19, 2018
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemiaChelsea Jenkins, Samuel B Luty, Julia E Maxson, et al.
Cancer Research|June 3, 2015
Therapeutically Targetable ALK Mutations in LeukemiaJulia E Maxson, Monika A Davare, Samuel B Luty, et al.
Haematologica|July 8, 2021
Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemiaJessica Leonard, Joelle Sj Wolf, Michelle Degnin, et al.
Experimental Hematology|April 24, 2017
Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemiaTakayo Sasaki, Juan Carlos Rivera-Mulia, Daniel Vera, et al.
Oncotarget|October 6, 2016
Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemiaNameeta P Richard, Raffaella Pippa, Megan M Cleary, et al.
Pageof 6